Rigel Pharmaceuticals, Inc./$RIGL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
- Ticker
- $RIGL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 173
- Headquarters
- South San Francisco, United States
- Website
- www.rigel.com
RIGL Metrics
BasicAdvanced
$881M
2.87
$16.45
1.17
-
Price and volume
Market cap
$881M
Beta
1.17
52-week high
$52.24
52-week low
$24.95
Average daily volume
231K
Financial strength
Current ratio
1.941
Quick ratio
1.584
Long term debt to equity
0
Total debt to equity
0.094
Interest coverage (TTM)
15.00%
Profitability
EBITDA (TTM)
89.699
Gross margin (TTM)
75.61%
Net profit margin (TTM)
116.30%
Operating margin (TTM)
31.45%
Effective tax rate (TTM)
-276.17%
Revenue per employee (TTM)
$1,600,000
Management effectiveness
Return on assets (TTM)
14.95%
Return on equity (TTM)
126.90%
Valuation
Price to earnings (TTM)
2.866
Price to revenue (TTM)
3.117
Price to book
2.07
Price to tangible book (TTM)
2.65
Price to free cash flow (TTM)
95.414
Free cash flow yield (TTM)
1.05%
Free cash flow per share (TTM)
0.494
Growth
Revenue change (TTM)
3.31%
Earnings per share change (TTM)
202.71%
3-year revenue growth (CAGR)
31.71%
10-year revenue growth (CAGR)
22.92%
3-year earnings per share growth (CAGR)
96.14%
10-year earnings per share growth (CAGR)
11.41%
Bulls say / Bears say
Rigel’s existing portfolio is growing and profitable: Q2 net product sales rose 14% year on year, with TAVALISSE up 18% and REZLIDHIA up 27%. The company raised its 2026 revenue guidance to $285–$295 million. (Rigel Pharmaceuticals)
VEPPANU gives Rigel a new growth opportunity in breast cancer: it is FDA-approved and commercially available, and its pivotal trial showed a significant improvement in progression-free survival over fulvestrant in patients with ESR1-mutated disease. (Rigel Pharmaceuticals)
R289 could add a further growth driver if early results hold up. Rigel reported a 33% response rate in a small, heavily pre-treated group in its Phase 1b study and expects to share dose-expansion data by year end. (StockAnalysis)
Eli Lilly has ended its RIPK1 collaboration, removing future milestone and royalty income and returning the programmes to Rigel. Lilly said ocadusertib did not meet its bar for continued development, raising questions about the asset’s prospects. (SEC, Fierce Biotech)
Rigel paid $70 million upfront to secure VEPPANU before its commercial launch was proven. If uptake is weak, that large outlay could be difficult to earn back and limit funds available for other priorities. (Rigel Pharmaceuticals)
Growth remains reliant on a few products, and there are signs that sales momentum may not be uniform: TAVALISSE made up most Q2 product sales and benefited from favourable inventory and gross-to-net dynamics, while GAVRETO sales fell 10% year on year. (The Motley Fool, Rigel Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
RIGL Financial Performance
Revenues and expenses
RIGL Earnings Performance
Company profitability
Upcoming events
No upcoming events
RIGL News
AllArticlesVideos
Funds containing RIGL
AllUSDGBPEUR
Fund name | Fund size | $RIGL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.